POINT Biopharma Global Inc. (NASDAQ:PNT) Receives $12.88 Consensus Price Target from Analysts
POINT Biopharma Global Inc. (NASDAQ:PNT – Get Free Report) has been given a consensus rating of “Hold” by the ten brokerages that are covering the stock, MarketBeat Ratings reports. Ten analysts have rated the stock with a hold recommendation. The average 1-year price objective among analysts that have issued a report on the stock in […]
More Stories
Byrna Technologies Inc. (NASDAQ:BYRN) Short Interest Up 10.1% in October
Byrna Technologies Inc. (NASDAQ:BYRN – Get Free Report) was the target of a large increase in short interest during the...
Brixmor Property Group (NYSE:BRX) Announces Quarterly Earnings Results, Misses Expectations By $0.21 EPS
Brixmor Property Group (NYSE:BRX – Get Free Report) issued its quarterly earnings results on Monday. The real estate investment trust...
CBAK Energy Technology, Inc. (NASDAQ:CBAT) Short Interest Update
CBAK Energy Technology, Inc. (NASDAQ:CBAT – Get Free Report) saw a large increase in short interest in October. As of...
Astar (ASTR) Hits Self Reported Market Capitalization of $416.87 Million
Astar (ASTR) traded 2% higher against the U.S. dollar during the 24 hour period ending at 21:00 PM Eastern on...
Boston Properties (NYSE:BXP) Releases FY 2024 Earnings Guidance
Boston Properties (NYSE:BXP – Get Free Report) issued an update on its FY 2024 earnings guidance on Tuesday morning. The...
Ripio Credit Network Price Tops $0.0017 on Major Exchanges (RCN)
Ripio Credit Network (RCN) traded 2.6% higher against the US dollar during the 24-hour period ending at 21:00 PM E.T....